Registration
Advertiser Disclosure

Biotechnology, Pharmaceuticals, and Research by Incyte

117.59
2.4500
2.04 %
At close 11/03
USD
USD
NASDAQ
Daily range
117.35 Arrow from to Icon 121.07
Weekly range
111.64 Arrow from to Icon 122.81
Live Price Short-Term Long-Term Signals Earnings Price History News
Incyte announces clinical trial collaboration with Genmab: Will INCY hold the MA-20?
  • Viktoras Karapetjanc
  • 24.10.2026
Incyte announces clinical trial collaboration with Genmab: Will INCY hold the MA-20?
Incyte announced a clinical trial collaboration with Genmab for patients with first-line metastatic colorectal cancer harboring a KRAS G12D mutation. The stock edges lower on the day, trading at ...
Why is Incyte stock down 2.8% today?
  • Hlib Chabaniuk
  • 13.10.2026
Why is Incyte stock down 2.8% today?
Incyte Corporation (INCY) dropped 2.88% as persistent short- and medium-term selling pressure continued to weigh on the stock. This decline is reinforced by Incyte's position below its 20- and ...
#Forecast
Incyte shares drop more than 3% after FDA approval for Atebrioz fails to lift sentiment
  • Jainam Mehta
  • 01.10.2026
Incyte shares drop more than 3% after FDA approval for Atebrioz fails to lift sentiment
Incyte Corporation (INCY) fell 3.2% after a downside gap, even as strong quarterly revenues and a recent FDA approval for Atebrioz set a positive backdrop. The drop is reinforced by the stock ...
#Forecast
$127.49 Incyte stock slips 1.88% after bullish run, Incyte focuses on atopic dermatitis awareness
  • Sholanke Dele
  • 30.07.2026
$127.49 Incyte stock slips 1.88% after bullish run, Incyte focuses on atopic dermatitis awareness
Incyte shared information about atopic dermatitis, describing it as a chronic inflammatory skin disease that can affect daily life.The company encouraged people to learn more about atopic ...
Incyte stock retreats as bullish momentum cools following EU approval for dermatitis drug
  • Sholanke Dele
  • 30.07.2026
Incyte stock retreats as bullish momentum cools following EU approval for dermatitis drug
Incyte says the European Commission has approved its topical JAK treatment for adults with moderate atopic dermatitis.The company shared the update in a tweet and included a link for more ...
Incyte stock edges higher to $118.87 as Q2 update is released, Incyte
  • Andreas Kristo
  • 28.07.2026
Incyte stock edges higher to $118.87 as Q2 update is released, Incyte
Incyte released a press statement about its second quarter financial results and business updates.The announcement invites readers to access further information online. Details are being ...
Incyte stock price forecast: $119.67 resistance in focus as INCY trades sideways
  • Oleg Tkachenko
  • 30.06.2026
Incyte stock price forecast: $119.67 resistance in focus as INCY trades sideways
Incyte (INCY) stock is trading at $114.2 in the latest session, posting a modest gain for the day. The stock remains above its key moving averages, signaling sustained ...
#Forecast
Incyte stock drops 6.04% despite new antibody data in myelofibrosis, Incyte reports
  • Emilio Ghigini
  • 16.06.2026
Incyte stock drops 6.04% despite new antibody data in myelofibrosis, Incyte reports
Incyte shared new positive data for its mutCALR-targeted monoclonal antibody in patients with myelofibrosis and essential thrombocythemia at the EHA Hematology Congress.The company invited ...
Who We Are
Business Solutions
For Users
TU News
Popular Sections
Disclosures
CONTACT US
Legal
We are in Social Media
© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186
  • Risk disclosure:

    Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

    That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.

  • Disclaimer:

    Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

    Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.

  • Disclosure of advertisers and revenues:

    All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

    Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.

onepercentfortheplanet.org https://gdpr.eu/ GDPR World Association of News Publishers